Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its...

|About: Corcept Therapeutics Inco... (CORT)|By:, SA News Editor

Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively.